Meeting
2021 ASCO Annual Meeting
Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.
Authors
Aung Naing
The University of Texas MD Anderson Cancer Center, Houston, TX
Aung Naing , Jean Fan , Byung Ha Lee , Debashree Basudhar , Shubham Pant , Marya F. Chaney , Cristina Laviada , Cynthia Rajan , Ngocdiep T. Le , Minal A. Barve
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT04332653
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2594)
DOI
10.1200/JCO.2021.39.15_suppl.2594
Abstract #
2594
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.
First Author: Aung Naing
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott
